Top Markets
Coin of the day
TWi Biotechnology, Inc. TWi Biotechnology, Inc.

TWi Biotechnology, Inc.

6610
Clasificación en acciones #17309
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
Precio por acción
$1.21
Capitalización bursátil
$248.41M
Cambio (1 día)
4.11%
Cambio (1 año)
79.12%
País
TW
Comercio TWi Biotechnology, Inc. (6610)

Categoría

Historial del precio de la acción de TWi Biotechnology, Inc. (6610)
Precio más alto de cierre: $1.18 el 2026-09-01

Precio más bajo de cierre: $1.95 el 2016-12-01
Historial del precio de la acción de TWi Biotechnology, Inc. desde 2016 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) 43.11%
2025 36.47%
2024 -13.49%
2023 13.07%
2022 -19.33%
2021 0.82%
2020 81.49%
2019 -54.47%
2018 -43.81%
2017 -42.56%
2016 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$554.04 38.16%
US
$1.05K 48.01%
NL
$148.48 513.79%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH